ERBA Diagnostics, Inc. Exhibits at MEDICA 2013, Dusseldorf Germany “World Forum for Medicine”

ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the World's largest medical show, MEDICA 2013 in Dusseldorf Germany Nov. 20-23.

While ERBA group will be showcasing its entire product range from its Global Subsidiaries that include the Elisa range for Auto Immune and Infectious Disease, Chemistry Analyzers, Hematology analyzers, Urine Analyzers and Coagulation systems along with the wide range of reagent kits we offer, we are particularly excited about the launching of two new high tech product offerings – the Laura XL and Hb–Vario.

First urine-based cancer mutation monitoring test available from Trovagene

Cell-free DNA assay transferred to CLIA laboratory for patient testing

Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, today announced availability of the first urine test for cancer mutation monitoring through the company's CLIA laboratory. The robustness of Trovagene's ultra-sensitive assay procedure has been demonstrated for detection of the BRAF V600E mutation from cell-free DNA in urine.  This mutation commonly occurs in melanoma, as well as several other prevalent cancer types.

Cancer Genetics, Inc. Featured in USA TODAY Article

Special Insert in the September 20 Print Edition of USA TODAY Also Features Panel Discussion With Cancer Genetics Founder, Dr. Raju Chaganti

Cancer Genetics, Inc. (CGIX) ("CGIX" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, was featured in an article in USA TODAY titled "Targeted therapy and companion diagnostics go hand and hand." The article is available online at:

http://us.mediaplanet.com/future-of-cancer-care/hand-in-hand-how-targeted-therapy-and-companion-diagnostics-are-changing-outcomes-for-cancer-patients

Pacific Biosciences Announces Agreement With Roche Diagnostics to Develop and Supply DNA Sequencing-Based Products for Clinical Diagnostics

Pacific Biosciences of California, Inc., (PACB), provider of the PacBio^(R) RS II DNA Sequencing System, today announced that it has entered into an agreement with Roche Diagnostics to develop diagnostic products, including sequencing systems and consumables, based on Pacific Biosciences' Single Molecule, Real-Time (SMRT^(R)) technology. Pacific Biosciences will develop and manufacture certain products intended for clinical use, which it will sell exclusively to Roche. Roche obtained worldwide rights to exclusively distribute these products in the field of human in vitro diagnostics. Pacific Biosciences will continue to market its current and future products for all fields outside of human in vitro diagnostics, including research, plant, animal, and applied markets.